Basic/Clinical Science Session
Expanding Role of GLP-1 Receptor Agonists for CKD Treatment
October 24, 2026 | 04:30 PM - 06:00 PM
Location: Four Seasons Ballroom 1, Convention Center
Session Description
GLP-1 receptor agonists (RAs) have emerged as new drugs to slow the progression of kidney diseases in people with type 2 diabetes and CKD. New hormones have been combined with GLP-1 RAs to enhance their potency in lowering glucose and reducing body weight. These new combinations, referred to as multihormone receptor modulators, are in development for the treatment of CKD. This session reviews the novel multihormone receptor modulators, summarizes their potential efficacy and safety, and examines their role in treating CKD.
Learning Objective(s)
- Describe the interaction between body weight, multihormone receptor modulators, and kidney function
- Outline new insights into the role of glucagon in kidney function
- Summarize the effects of amylin on the pancreas and kidneys
- Evaluate the liver-kidney axis and the role of fibroblast growth factor 21 (FGF-21)
Learning Pathway(s)
- Cardiovascular-Kidney-Metabolic (CKM) Health
- Pharmacology
Moderators
Presentations
- Epidemic of Obesity and Kidney Diseases: From Prevalence to Therapies
04:30 PM - 04:50 PM
- Role of Glucagon in the Kidneys: Friend or Foe?
04:50 PM - 05:10 PM
- Could Targeting Amylin Protect the Kidneys?
05:10 PM - 05:30 PM
- The Liver-Kidney Axis and the Role of FGF-21
05:30 PM - 05:50 PM
- Q&A
05:50 PM - 06:00 PM